“P&G Health’s ₹10,500 Cr Vitamin Empire: Evion for Muscles, Neurobion for Nerves, and 35x P/E for Investors’ Patience”
1. At a Glance
P&G Health (PGHL), formerly Merck India, is the FMCG kid who snuck into pharma class. With brands like Neurobion, Evion, Livogen, and Nasivion, they sell vitamins, minerals, and supplements (VMS) at margins that make generic pharma cry. FY25 PAT jumped 43%, ROCE is a sizzling 48%, and ROE 36%. The catch? Sales growth is flatter than diet soda—just 0.2% over 5 years. Yet the market happily pays 35x earnings, proving Indians will overpay for branded vitamins as much as they do for overpriced protein powders.
2. Introduction
P&G Health’s story is corporate jugaad done right: buy Merck’s consumer health portfolio, slap P&G’s marketing muscle on it, and watch Amitabh Bachchan sell Neurobion Forte to every Indian uncle with “nerve pain.”
The company thrives in the vitamins and supplements market, which is booming thanks to sedentary lifestyles, junk food diets, and wellness paranoia. Evion is India’s Vitamin E darling, Neurobion is basically a B-vitamin subscription plan, and Nasivion rules nasal decongestants like Salman Khan rules Eid releases.
But behind the glossy campaigns lies a paradox: sales barely grow, volumes are flat, and debtor days are stretching. It’s like an overachieving student who scores 99 in practicals but fails theory. Investors are left wondering: is PGHL a high-margin gem or just a vitamin bubble?
Question: would you rather invest in a company growing fast but with lower margins, or one with fat margins but no growth pulse?
3. Business Model – WTF Do They Even Do?
P&G Health is not inventing life-saving drugs. It’s running a well-oiled vitamin FMCG machine:
Vitamins & Supplements: Evion (Vitamin E), Neurobion (B vitamins), Polybion, Livogen. Basically, a branded alphabet soup of pills.
New Launches & Upgrades: Mango-flavored Polybion Active, Neurobion Alfa D, upgraded injections. Because who doesn’t want their vitamins in fruit juice cosplay?
Distribution Muscle: Shifted to a “super distributor” model—less like pharma reps, more like D-Mart for chemists.
Geographic Reach: Strong urban presence, now pushing into rural areas and e-pharmacies (Pharmeasy, 1MG).
So yes, PGHL is pharma by license, FMCG by execution, and Bollywood by marketing.
4. Financials Overview
Metric
Latest Qtr (Jun’25)
YoY Qtr (Jun’24)
Prev Qtr (Mar’25)
YoY %
QoQ %
Revenue
₹339 Cr
₹284 Cr
₹311 Cr
19.3%
9.0%
EBITDA
₹90 Cr
₹48 Cr
₹81 Cr
87.5%
11.1%
PAT
₹66.2 Cr
₹25.6 Cr
₹61 Cr
158%
8.5%
EPS (₹)
39.9
10.1
36.9
294%
8.1%
Commentary: This quarter looks juiced up like a gym bro on Evion. Sales grew 19%, PAT more than doubled. But remember: one good quarter does not fix a 5-year growth headache.
5. Valuation – Fair Value Range Only
P/E Method: EPS TTM = ₹181. Industry P/E ~32. Fair Value = ₹5,000 – ₹6,500.
EV/EBITDA Method: EBITDA TTM ~₹409 Cr. EV = ₹10,393 Cr → EV/EBITDA = 25x. Sector median ~18–20x. Fair Value = ₹7,000 – ₹8,200 Cr → per share ₹4,200 – ₹5,000.
DCF (Vitamin Math): Assume 8% revenue growth, 28% net margin, discount rate 12%. Fair Value = ₹5,200 – ₹6,000.
Fair Value Range: ₹4,200 – ₹6,500.
Disclaimer: This fair value range is for educational purposes only and is not investment advice.
6. What’s Cooking – News, Triggers, Drama
Celebrity Marketing: Amitabh Bachchan selling Neurobion. When Big B tells you to “care for your nerves,” you listen—even if your nerves are frayed from stock market losses.
Super Distributor Model: Transition complete; better pharmacy reach, rural expansion. Basically, more chemists nagging you to try Evion.
New Launches: Polybion Active Mango, Neurobion Alfa
